 <h1>Ganciclovir Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of ganciclovir include:</b> severe neutropenia, severe thrombocytopenia, anemia, leukopenia, neutropenia, and decreased creatinine clearance. <b>Other side effects include:</b> severe anemia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ganciclovir: powder for solution, solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule)</p><p>The clinical toxicity of ganciclovir includes granulocytopenia, anemia, and thrombocytopenia. Ganciclovir capsules are indicated only for prevention of cytomegalovirus (CMV) disease in patients with advanced HIV infection at risk for CMV disease, for maintenance treatment of CMV retinitis in immunocompromised patients, and for prevention of CMV disease in solid organ transplant recipients. Because ganciclovir is associated with a risk of more rapid rate of CMV retinitis progression, it should be used as maintenance treatment only in those patients for whom this risk is balanced by the benefit associated with avoiding daily IV infusions.</p><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir sodium. Based on animal data and limited human data, ganciclovir sodium may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females. Based on animal data, ganciclovir sodium has the potential to cause birth defects in humans. Based on animal data, ganciclovir sodium has the potential to cause cancers in humans.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ganciclovir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>Medicines like ganciclovir can sometimes cause serious side effects such as blood problems; these are described below. Discuss these possible effects with your doctor.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ganciclovir:</p><p>
<i>More common</i>
</p><p>
<i>For oral capsules and injection into the vein only</i>
</p><ul>
<li>Sore throat and fever</li>
<li>unusual bleeding or bruising</li>
</ul><p>
<i>Less common</i>
</p><p>
<i>For oral capsules and injection into the vein only</i>
</p><ul>
<li>Mood or other mental changes</li>
<li>nervousness </li>
<li>pain at place of injection</li>
<li> skin rash</li>
<li>tremor</li>
<li>unusual tiredness and weakness</li>
</ul><p>
<i>For injection into the eye only</i>
</p><ul>
<li>Decreased vision or any change in vision</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ganciclovir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>loss of appetite </li>
<li>nausea and vomiting</li>
</ul><p>
<!-- end powder for solution, solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ganciclovir: intravenous powder for injection, intravenous solution, oral capsule</i></p><h3>General</h3><p>The most commonly reported adverse events have included pyrexia, diarrhea, leukopenia, nausea, anemia, asthenia, headache, cough, dyspnea, abdominal pain, decreased appetite, and increased creatinine.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>During clinical trials for the treatment of CMV retinitis, neutropenia with absolute neutrophil count (ANC) less than 500, between 500 and 749, and 750 to less than 1000 mcL, was reported in 25%, 14%, and 26% of patients, respectively. Anemia with hemoglobin less than 6.5, between 6.5 and less than 8, and 8 to less than 9.5 g/dL was reported in 5%, 16%, and 26% of patients, respectively. </p>
<p></p>
<p>During clinical trials among transplant recipients receiving this drug for CMV prevention, neutropenia with absolute neutrophil count (ANC) less than 500, between 500 and 1000 mcL, and total ANC of 1000 mcL or less was reported in 4%, 3% and 7% of heart transplant recipients and 12%, 29%, and 41% of bone marrow transplant recipients, respectively.  Thrombocytopenia with platelet counts less than 25,000 and between 25,000 and 50,000 mcL were reported in 3% and 5% and 32% and 25% of heart and bone marrow recipients, respectively. Total platelet count of 50,000 mcL or less was reported in 8% and 57% of heart and bone marrow recipients, respectively.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Leukopenia (up to 41%), anemia (up to 26%), neutropenia (up to 26%)</p>
<p><b>Common</b> (1% to 10%): Thrombocytopenia, lymphadenopathy </p>
<p><b>Uncommon</b> (0.1% to 1%): Bone marrow failure</p>
<p><b>Frequency not reported</b>: Pancytopenia </p>
<p><b>Postmarketing reports</b>: Hemolytic anemia, agranulocytosis, granulocytopenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 44%), vomiting 13%</p>
<p><b>Common</b> (1% to 10%): Nausea, abdominal pain, constipation, flatulence, esophageal candidiasis, dysphagia, dyspepsia</p>
<p><b>Uncommon</b> (0.1% to 1%): Mouth ulceration, abdominal distention, pancreatitis</p>
<p><b>Frequency not reported</b>: Gastrointestinal perforation, eructation, dry mouth, pancreatitis</p>
<p><b>Postmarketing reports</b>: Intestinal ulcer<sup>[Ref]</sup></p><h3>Renal</h3><p>Elevated serum creatinine between greater than 1.5 and less than 2.5 mg/dL was reported in 14% of patients receiving 5 mg/kg/day for treatment of CMV retinitis; 2% experienced elevated serum creatinine of 2.5 mg/dL or greater. </p>
<p></p>
<p>Elevated serum creatinine between greater than 1.5 and less than 2.5 mg/dL was reported in 58%, 50%, and 43% of patients receiving this drug for CMV prevention in heart, and 2 bone marrow trials, respectively; 18%, 20%, and 0% experienced serum creatinine levels of 2.5 mg/dL or higher.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Elevated serum creatinine</p>
<p><b>Frequency not reported</b>: Kidney failure, abnormal renal function, pleural effusion</p>
<p><b>Postmarketing reports</b>: Renal tubular disorder, hemolytic uremic syndrome<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection, urinary frequency, hematuria</p>
<p><b>Postmarketing reports</b>: Testicular hypertrophy<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity</p>
<p><b>Postmarketing reports</b>: Anaphylactic reaction, allergic reaction<sup>[Ref]</sup></p><h3>Ocular</h3><p>Retinal detachment has been observed both before and after initiation of therapy in patients with CMV retinitis; its relationship to therapy is unknown.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Retinal detachment (11%) </p>
<p><b>Common</b> (1% to 10%): Eye hemorrhage, macular edema, vitreous floaters, eye pain</p>
<p><b>Frequency not reported</b>: Visual impairment, vitreous disorders, eye pain, conjunctivitis </p>
<p><b>Postmarketing reports</b>: Cataracts, dry eyes<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Tachycardia (16%), hypotension (11%) </p>
<p><b>Frequency not reported</b>: Arrhythmias, chest pain, hypertension, phlebitis, vasodilation</p>
<p><b>Postmarketing reports</b>: Cardiac arrest, conduction disorder, torsade de pointes, ventricular tachycardia, peripheral ischemia<sup>[Ref]</sup></p><p>Cases of ventricular tachycardia associated with ganciclovir infusions in patients with AIDS have been reported, although it is known that HIV infection is associated with myocarditis, decreased left ventricular function, and in some cases, nonsustained ventricular tachycardia.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hyperhidrosis (12%)</p>
<p><b>Common</b> (1% to 10%): Pruritus, dermatitis, night sweats</p>
<p><b>Frequency not reported</b>: Cellulitis, alopecia, dry skin, urticaria, rash, photosensitivity reaction</p>
<p><b>Postmarketing reports</b>: Exfoliative dermatitis, Stevens-Johnson syndrome<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased alkaline phosphatase</p>
<p><b>Frequency not reported</b>: Abnormal hepatic function tests, increased transaminases</p>
<p><b>Postmarketing reports</b>: Cholelithiasis, cholestasis, hepatic failure, hepatitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (15%) </p>
<p><b>Common</b> (1% to 10%): Peripheral neuropathy, tremor, dizziness, paresthesia, hypoesthesia, seizures, dysgeusia </p>
<p><b>Frequency not reported</b>:  Somnolence</p>
<p><b>Postmarketing reports</b>:  Dysesthesia, dysphasia, extrapyramidal disorder, facial paralysis, amnesia, anosmia, myelopathy, cerebrovascular accident, third cranial nerve paralysis, aphasia, encephalopathy, intracranial hypertension, facial palsy<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Postmarketing reports</b>: Inappropriate antidiuretic hormone secretion, infertility<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Catheter infection, catheter sepsis, injection site inflammation, </p>
<p>other catheter related events</p>
<p><b>Frequency not reported</b>: Injection site inflammation<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (14%), decreased blood magnesium (11%)</p>
<p><b>Common</b> (1% to 10%): Decreased weight, anorexia</p>
<p><b>Frequency not reported</b>: Hypocalcemia, hypokalemia, hyperglycemia</p>
<p><b>Postmarketing reports</b>: Acidosis, hypercalcemia, hyponatremia, increased blood triglycerides<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, myalgia, back pain, muscle spasms</p>
<p><b>Frequency not reported</b>: Leg cramps, myasthenia </p>
<p><b>Postmarketing reports</b>: Arthritis, rhabdomyolysis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (16%) </p>
<p><b>Common</b> (1% to 10%): Pneumocystis carinii pneumonia, sinus congestion, rhinitis, dyspnea</p>
<p><b>Frequency not reported</b>: Upper respiratory infection</p>
<p><b>Postmarketing reports</b>: Bronchospasm, pulmonary fibrosis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (up to 48%) </p>
<p><b>Common</b> (1% to 10%): Chills</p>
<p><b>Uncommon</b> (0.1% to 1%): Deafness</p>
<p><b>Frequency not reported</b>: Tinnitus, ear pain, fatigue, pain, malaise, asthenia, multiple organ failure</p>
<p><b>Postmarketing reports</b>: Congenital anomaly, loss of sense of smell<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Sepsis (15%), infection (13%)</p>
<p><b>Common</b> (1% to 10%): Mycobacterium avium complex </p>
<p><b>Frequency not reported</b>: Candida infections, influenza</p>
<p><b>Postmarketing reports</b>: Vasculitis<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Cytovene (ganciclovir)." Genentech, South San Francisco, CA. </p><p id="ref_2">2. Tomonari A,  Takahashi S,  Ooi J, et al. "Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after unrelated cord blood transplantation." Bone Marrow Transplant  (2007):</p><p id="ref_3">3. Sulecki M, Rosenfeld CS, Przepiorka D, et al "Treatment of ganciclovir-induced neutropenia with recombinant human GM-CSF." Am J Med 90 (1991): 401-2</p><p id="ref_4">4. Wiltshire H,  Paya CV,  Pescovitz MD, et al. "Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients." Transplantation 79 (2005): 1477-1483</p><p id="ref_5">5. Slifkin M,  Doron S,  Snydman DR "Viral prophylaxis in organ transplant patients." Drugs 64 (2004): 2763-92</p><p id="ref_6">6. Reischig T,  Jindra P,  Mares J, et al. "Valacyclovir for Cytomegalovirus Prophylaxis Reduces the Risk of Acute Renal Allograft Rejection." Transplantation 79 (2005): 317-324</p><p id="ref_7">7. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M "Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factor and outcome." Blood 90 (1997): 2502-8</p><p id="ref_8">8. Asano-Mori Y,  Kanda Y,  Oshima K, et al. "Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment." J Antimicrob Chemother 57 (2006): 1004-7</p><p id="ref_9">9. Hayashi K,  Mori J,  Saito H,  Hayashi T "Antiviral targets of a chromene derivative from Sargassum micracanthum in the replication of human cytomegalovirus." Biol Pharm Bull 29 (2006): 1843-7</p><p id="ref_10">10. Goodrich JM, Mori M, Gleaves CA, et al "Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation." N Engl J Med 325 (1991): 1601-7</p><p id="ref_11">11. SOCA Reseach Group, et al "Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis." N Engl J Med 326 (1992): 213-20</p><p id="ref_12">12. Faulds D, Heel RC "Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections." Drugs 39 (1990): 597-638</p><p id="ref_13">13. Reed EC, Wolford JL, Kopecky KJ, et al "Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients." Ann Intern Med 112 (1990): 505-10</p><p id="ref_14">14. Cochrane AB "Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients." Am J Health Syst Pharm 63(19 Suppl 5) (2006): S17-21</p><p id="ref_15">15. Jabs DA "The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The ganciclovir cidofovir cytomegalovirus retinitis trial." Am J Ophthalmol 131 (2001): 457-67</p><p id="ref_16">16. Takami A,  Mochizuki K,  Ito S, et al. "Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation." Transplant Proc 39 (2007): 237-9</p><p id="ref_17">17. Schmidt GM, Horak DA, Niland JC, et al "A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants." N Engl J Med 324 (1991): 1005-12</p><p id="ref_18">18. Taegtmeyer AB,  Halil O,  Bell AD,  Carby M,  Cummins D,  Banner NR "Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir." Transplantation 80 (2005): 127-30</p><p id="ref_19">19. Keven K,  Basu A,  Tan HP, et al. "Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning." Transplant Proc 36 (2004): 3107-12</p><p id="ref_20">20. Whitely RJ "Ganciclovir: have we established clinical value in the treatment of cytomegalovirus infections?" Ann Intern Med 108 (1988): 452-4</p><p id="ref_21">21. Figge HL, Bailie GR, Briceland LL, Kowalsky SF "Possible ganciclovir-induced hepatotoxicity in patients with aids." Clin Pharm 11 (1992): 432-4</p><p id="ref_22">22. Izzedine H,  Launay-Vacher V,  Deray G "Antiviral drug-induced nephrotoxicity." Am J Kidney Dis 45 (2005): 804-17</p><p id="ref_23">23. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al "Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in aids." Ophthalmology 98 (1991): 1348-55</p><p id="ref_24">24. Cohen AJ, Weiser B, Afzal Q, Fuhrer J "Ventricular tachycardia in two patients with aids receiving ganciclovir (DHPG)." AIDS 4 (1990): 807-9</p><p id="ref_25">25. Marcollo Pini A,  Kerl K,  Kamarachev J,  French LE,  Hofbauer GF "Interstitial granulomatous drug reaction following intravenous ganciclovir." Br J Dermatol 158 (2008): 1391-3</p><p id="ref_26">26. Davis CL, Springmeyer S, Gmerek BJ "Central nervous system side effects of ganciclovir." N Engl J Med 322 (1990): 933-4</p><p id="ref_27">27. Ernst ME, Franey RJ "Acyclovir- and ganciclovir-induced neurotoxicity." Ann Pharmacother 32 (1998): 111-3</p><p id="ref_28">28. Schiff HB "More on ganciclovir-induced "psychosis"." N Engl J Med 336 (1997): 1190</p><p id="ref_29">29. Hansen BA, Greenberg KS, Richter JA "Ganciclovir-induced psychosis." N Engl J Med 335 (1996): 1397</p><p id="ref_30">30. Georgiev OP, Lal SM, Gupta N, Ross G "Ganciclovir-associated hypercalcemia in a renal transplant patient." Int J Artif Organs 21 (1998): 702-4</p></div>
<div class="more-resources" id="moreResources">
<h2>More about ganciclovir</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: purine nucleosides</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ganciclovir Oral, Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Cytovene</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>CMV Infection</li>
<li>CMV Prophylaxis</li>
<li>CMV Retinitis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ganciclovir: intravenous powder for injection, intravenous solution, oral capsule</i></p><h3>General</h3><p>The most commonly reported adverse events have included pyrexia, diarrhea, leukopenia, nausea, anemia, asthenia, headache, cough, dyspnea, abdominal pain, decreased appetite, and increased creatinine.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>During clinical trials for the treatment of CMV retinitis, neutropenia with absolute neutrophil count (ANC) less than 500, between 500 and 749, and 750 to less than 1000 mcL, was reported in 25%, 14%, and 26% of patients, respectively. Anemia with hemoglobin less than 6.5, between 6.5 and less than 8, and 8 to less than 9.5 g/dL was reported in 5%, 16%, and 26% of patients, respectively. </p><p></p><p>During clinical trials among transplant recipients receiving this drug for CMV prevention, neutropenia with absolute neutrophil count (ANC) less than 500, between 500 and 1000 mcL, and total ANC of 1000 mcL or less was reported in 4%, 3% and 7% of heart transplant recipients and 12%, 29%, and 41% of bone marrow transplant recipients, respectively.  Thrombocytopenia with platelet counts less than 25,000 and between 25,000 and 50,000 mcL were reported in 3% and 5% and 32% and 25% of heart and bone marrow recipients, respectively. Total platelet count of 50,000 mcL or less was reported in 8% and 57% of heart and bone marrow recipients, respectively.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Leukopenia (up to 41%), anemia (up to 26%), neutropenia (up to 26%)</p><p><b>Common</b> (1% to 10%): Thrombocytopenia, lymphadenopathy </p><p><b>Uncommon</b> (0.1% to 1%): Bone marrow failure</p><p><b>Frequency not reported</b>: Pancytopenia </p><p><b>Postmarketing reports</b>: Hemolytic anemia, agranulocytosis, granulocytopenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 44%), vomiting 13%</p><p><b>Common</b> (1% to 10%): Nausea, abdominal pain, constipation, flatulence, esophageal candidiasis, dysphagia, dyspepsia</p><p><b>Uncommon</b> (0.1% to 1%): Mouth ulceration, abdominal distention, pancreatitis</p><p><b>Frequency not reported</b>: Gastrointestinal perforation, eructation, dry mouth, pancreatitis</p><p><b>Postmarketing reports</b>: Intestinal ulcer<sup>[Ref]</sup></p><h3>Renal</h3><p>Elevated serum creatinine between greater than 1.5 and less than 2.5 mg/dL was reported in 14% of patients receiving 5 mg/kg/day for treatment of CMV retinitis; 2% experienced elevated serum creatinine of 2.5 mg/dL or greater. </p><p></p><p>Elevated serum creatinine between greater than 1.5 and less than 2.5 mg/dL was reported in 58%, 50%, and 43% of patients receiving this drug for CMV prevention in heart, and 2 bone marrow trials, respectively; 18%, 20%, and 0% experienced serum creatinine levels of 2.5 mg/dL or higher.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Elevated serum creatinine</p><p><b>Frequency not reported</b>: Kidney failure, abnormal renal function, pleural effusion</p><p><b>Postmarketing reports</b>: Renal tubular disorder, hemolytic uremic syndrome<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection, urinary frequency, hematuria</p><p><b>Postmarketing reports</b>: Testicular hypertrophy<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity</p><p><b>Postmarketing reports</b>: Anaphylactic reaction, allergic reaction<sup>[Ref]</sup></p><h3>Ocular</h3><p>Retinal detachment has been observed both before and after initiation of therapy in patients with CMV retinitis; its relationship to therapy is unknown.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Retinal detachment (11%) </p><p><b>Common</b> (1% to 10%): Eye hemorrhage, macular edema, vitreous floaters, eye pain</p><p><b>Frequency not reported</b>: Visual impairment, vitreous disorders, eye pain, conjunctivitis </p><p><b>Postmarketing reports</b>: Cataracts, dry eyes<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Tachycardia (16%), hypotension (11%) </p><p><b>Frequency not reported</b>: Arrhythmias, chest pain, hypertension, phlebitis, vasodilation</p><p><b>Postmarketing reports</b>: Cardiac arrest, conduction disorder, torsade de pointes, ventricular tachycardia, peripheral ischemia<sup>[Ref]</sup></p><p>Cases of ventricular tachycardia associated with ganciclovir infusions in patients with AIDS have been reported, although it is known that HIV infection is associated with myocarditis, decreased left ventricular function, and in some cases, nonsustained ventricular tachycardia.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hyperhidrosis (12%)</p><p><b>Common</b> (1% to 10%): Pruritus, dermatitis, night sweats</p><p><b>Frequency not reported</b>: Cellulitis, alopecia, dry skin, urticaria, rash, photosensitivity reaction</p><p><b>Postmarketing reports</b>: Exfoliative dermatitis, Stevens-Johnson syndrome<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased alkaline phosphatase</p><p><b>Frequency not reported</b>: Abnormal hepatic function tests, increased transaminases</p><p><b>Postmarketing reports</b>: Cholelithiasis, cholestasis, hepatic failure, hepatitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (15%) </p><p><b>Common</b> (1% to 10%): Peripheral neuropathy, tremor, dizziness, paresthesia, hypoesthesia, seizures, dysgeusia </p><p><b>Frequency not reported</b>:  Somnolence</p><p><b>Postmarketing reports</b>:  Dysesthesia, dysphasia, extrapyramidal disorder, facial paralysis, amnesia, anosmia, myelopathy, cerebrovascular accident, third cranial nerve paralysis, aphasia, encephalopathy, intracranial hypertension, facial palsy<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Postmarketing reports</b>: Inappropriate antidiuretic hormone secretion, infertility<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Catheter infection, catheter sepsis, injection site inflammation, </p><p>other catheter related events</p><p><b>Frequency not reported</b>: Injection site inflammation<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (14%), decreased blood magnesium (11%)</p><p><b>Common</b> (1% to 10%): Decreased weight, anorexia</p><p><b>Frequency not reported</b>: Hypocalcemia, hypokalemia, hyperglycemia</p><p><b>Postmarketing reports</b>: Acidosis, hypercalcemia, hyponatremia, increased blood triglycerides<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, myalgia, back pain, muscle spasms</p><p><b>Frequency not reported</b>: Leg cramps, myasthenia </p><p><b>Postmarketing reports</b>: Arthritis, rhabdomyolysis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (16%) </p><p><b>Common</b> (1% to 10%): Pneumocystis carinii pneumonia, sinus congestion, rhinitis, dyspnea</p><p><b>Frequency not reported</b>: Upper respiratory infection</p><p><b>Postmarketing reports</b>: Bronchospasm, pulmonary fibrosis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (up to 48%) </p><p><b>Common</b> (1% to 10%): Chills</p><p><b>Uncommon</b> (0.1% to 1%): Deafness</p><p><b>Frequency not reported</b>: Tinnitus, ear pain, fatigue, pain, malaise, asthenia, multiple organ failure</p><p><b>Postmarketing reports</b>: Congenital anomaly, loss of sense of smell<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Sepsis (15%), infection (13%)</p><p><b>Common</b> (1% to 10%): Mycobacterium avium complex </p><p><b>Frequency not reported</b>: Candida infections, influenza</p><p><b>Postmarketing reports</b>: Vasculitis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Cytovene (ganciclovir)." Genentech, South San Francisco, CA. </p><p id="ref_2">2. Tomonari A,  Takahashi S,  Ooi J, et al. "Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after unrelated cord blood transplantation." Bone Marrow Transplant  (2007):</p><p id="ref_3">3. Sulecki M, Rosenfeld CS, Przepiorka D, et al "Treatment of ganciclovir-induced neutropenia with recombinant human GM-CSF." Am J Med 90 (1991): 401-2</p><p id="ref_4">4. Wiltshire H,  Paya CV,  Pescovitz MD, et al. "Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients." Transplantation 79 (2005): 1477-1483</p><p id="ref_5">5. Slifkin M,  Doron S,  Snydman DR "Viral prophylaxis in organ transplant patients." Drugs 64 (2004): 2763-92</p><p id="ref_6">6. Reischig T,  Jindra P,  Mares J, et al. "Valacyclovir for Cytomegalovirus Prophylaxis Reduces the Risk of Acute Renal Allograft Rejection." Transplantation 79 (2005): 317-324</p><p id="ref_7">7. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M "Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factor and outcome." Blood 90 (1997): 2502-8</p><p id="ref_8">8. Asano-Mori Y,  Kanda Y,  Oshima K, et al. "Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment." J Antimicrob Chemother 57 (2006): 1004-7</p><p id="ref_9">9. Hayashi K,  Mori J,  Saito H,  Hayashi T "Antiviral targets of a chromene derivative from Sargassum micracanthum in the replication of human cytomegalovirus." Biol Pharm Bull 29 (2006): 1843-7</p><p id="ref_10">10. Goodrich JM, Mori M, Gleaves CA, et al "Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation." N Engl J Med 325 (1991): 1601-7</p><p id="ref_11">11. SOCA Reseach Group, et al "Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis." N Engl J Med 326 (1992): 213-20</p><p id="ref_12">12. Faulds D, Heel RC "Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections." Drugs 39 (1990): 597-638</p><p id="ref_13">13. Reed EC, Wolford JL, Kopecky KJ, et al "Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients." Ann Intern Med 112 (1990): 505-10</p><p id="ref_14">14. Cochrane AB "Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients." Am J Health Syst Pharm 63(19 Suppl 5) (2006): S17-21</p><p id="ref_15">15. Jabs DA "The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The ganciclovir cidofovir cytomegalovirus retinitis trial." Am J Ophthalmol 131 (2001): 457-67</p><p id="ref_16">16. Takami A,  Mochizuki K,  Ito S, et al. "Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation." Transplant Proc 39 (2007): 237-9</p><p id="ref_17">17. Schmidt GM, Horak DA, Niland JC, et al "A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants." N Engl J Med 324 (1991): 1005-12</p><p id="ref_18">18. Taegtmeyer AB,  Halil O,  Bell AD,  Carby M,  Cummins D,  Banner NR "Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir." Transplantation 80 (2005): 127-30</p><p id="ref_19">19. Keven K,  Basu A,  Tan HP, et al. "Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning." Transplant Proc 36 (2004): 3107-12</p><p id="ref_20">20. Whitely RJ "Ganciclovir: have we established clinical value in the treatment of cytomegalovirus infections?" Ann Intern Med 108 (1988): 452-4</p><p id="ref_21">21. Figge HL, Bailie GR, Briceland LL, Kowalsky SF "Possible ganciclovir-induced hepatotoxicity in patients with aids." Clin Pharm 11 (1992): 432-4</p><p id="ref_22">22. Izzedine H,  Launay-Vacher V,  Deray G "Antiviral drug-induced nephrotoxicity." Am J Kidney Dis 45 (2005): 804-17</p><p id="ref_23">23. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al "Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in aids." Ophthalmology 98 (1991): 1348-55</p><p id="ref_24">24. Cohen AJ, Weiser B, Afzal Q, Fuhrer J "Ventricular tachycardia in two patients with aids receiving ganciclovir (DHPG)." AIDS 4 (1990): 807-9</p><p id="ref_25">25. Marcollo Pini A,  Kerl K,  Kamarachev J,  French LE,  Hofbauer GF "Interstitial granulomatous drug reaction following intravenous ganciclovir." Br J Dermatol 158 (2008): 1391-3</p><p id="ref_26">26. Davis CL, Springmeyer S, Gmerek BJ "Central nervous system side effects of ganciclovir." N Engl J Med 322 (1990): 933-4</p><p id="ref_27">27. Ernst ME, Franey RJ "Acyclovir- and ganciclovir-induced neurotoxicity." Ann Pharmacother 32 (1998): 111-3</p><p id="ref_28">28. Schiff HB "More on ganciclovir-induced "psychosis"." N Engl J Med 336 (1997): 1190</p><p id="ref_29">29. Hansen BA, Greenberg KS, Richter JA "Ganciclovir-induced psychosis." N Engl J Med 335 (1996): 1397</p><p id="ref_30">30. Georgiev OP, Lal SM, Gupta N, Ross G "Ganciclovir-associated hypercalcemia in a renal transplant patient." Int J Artif Organs 21 (1998): 702-4</p><h2>More about ganciclovir</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: purine nucleosides</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ganciclovir Oral, Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>CMV Infection</li>
<li>CMV Prophylaxis</li>
<li>CMV Retinitis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>